Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LAUREN

Financiado

Cerrado

bLadder cAncer URine cEll aNalysis

Bladder cancer is the 4th most common cancer in men and the 7th in women, with 330,000- 380,000 new cases annually worldwide or more than 150,000 in Europe and is one of the most expensive cancers to manage. Bladder cancer incide... ver más

31/07/2018

CYTO

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

CYTOSYSTEMS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-07-31

PHC-12-2014: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CYTO

3.14M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BLACANDI BLACANDI can improve life quality and cut cost of diagnosing... 71K€ Cerrado

URO-BEST UROthelial carcinoma Biomarker based diagnostic tEST 71K€ Cerrado

OneRNA4Bladder Non invasive Cell Based Liquid Biopsy Platform for Bladder C... 4M€ Cerrado

Cancersensing A multi cancer screening platform for fast and accurate earl... 71K€ Cerrado

PROSTATOR Reliable urinary test for the diagnosis of prostate cancer 150K€ Cerrado

BlaC E-assay Portable electrochemical assay system for on chip quantitati... 195K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2015-06-18
Fecha Fin: 2018-07-31

Líder del proyecto

CYTOSYSTEMS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bladder cancer is the 4th most common cancer in men and the 7th in women, with 330,000- 380,000 new cases annually worldwide or more than 150,000 in Europe and is one of the most expensive cancers to manage. Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older men and women. Cystoscopy/cystoscopic biopsy remains the current gold standard diagnostic and monitoring tool. This procedure is highly invasive and expensive - costing up to €1200 per test - and has been reported to miss in the region of 25% of all bladder tumours. As an adjunct to cystoscopy, urine cytology is routinely carried out globally but its deficiencies in terms of poor cancer detection (low sensitivity) are well recognised and reported. The overall objective of the LAUREN project is to provide a commercial non-invasive in vitro diagnostic that will significantly reduce the management cost of caring for bladder cancer patients, whilst at the same time improving patient comfort and reducing morbidity associated with current invasive procedures. The specific diagnostic is based on the MCM2 + Immunofluorescence biomarker for bladder cancer cells found in urine.The scope of the project is to complete the final development, validation and regulatory activities required to prepare a novel the new diagnostic for the market. The objectives of the project are to: PO1 Clinically validate the biomarkers including the addition of Immuno Fluorescence PO2 Complete development of and validate a single use cell collection device, PO3 Validate the cell recognition software for regulatory acceptance PO4 Validate the software of an automated slide analysis system. PO5 Prepare a complete evidence package to support obtaining a CE Mark and FDA approval for commercialisation

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores